
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **December 2015**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 A Slide Presentation for Investors – December 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.
(Registrant)

By: /s/ Sigal Fattal

Sigal Fattal
Chief Financial Officer

Date: December 30, 2015

EXHIBIT INDEX

<u>EXHIBIT NO.</u>	<u>DESCRIPTION</u>
99.1	A Slide Presentation for Investors – December 2015.

A decorative horizontal banner with a wavy, undulating shape. It contains two photographs: the top part shows several green grass-like plants growing in dark soil, and the bottom part shows a gloved hand using tweezers to place a small green seedling into a black tray.

Introduction to Evogene

Ofer Haviv, President & CEO

December, 2015

Safe Harbor Statement

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

Introducing Evogene


► We are...

A leading ag biotechnology company for the improvement of crop productivity and performance, addressing the increasing demand for food, feed and fuel

Introducing Evogene



- **Founded** in 2002
- **Located** -
 - HQ : Rehovot, Israel
 - R&D site : St. Louis, USA
- **~200** employees, **80%** R&D
- **Two R&D hubs for improving crop productivity** -
 - Crop enhancement - yield, drought tolerance and fertilizer use efficiency
 - Crop protection - insect resistance, disease, weeds
- **Targeting 3 major markets** - seed traits (~\$40B*); ag-chemicals (~\$55B**); ag-biologicals (~\$3.2B***)
- **Addressing markets** through collaborations with world-leading agriculture companies
- **Over 1,000 genes in field trial validation** - within partners' pipelines



* Source: Phillips McDougall

** Source: Phillips McDougall, 2014


*** Source: Piper Jaffray 2013, Agrow 2014

The need for innovation




The need: provide more with less

World population



Arable land per capita



Farmer will always want better yield - best seed products and lower input costs

The solution: increasing crop productivity and performance

Improved Seed Traits



Innovative Ag-Chemicals



Novel Ag-Biologicals



Evogene's approach for ag-innovation: utilizing scientific understanding and computational technologies to harness the potential of the Ag 'big data' revolution

Ag 'big data' - an opportunity for ag-innovation

Ag 'big data' "hidden product"



>10's M
plant genes


>100's M
microbial strains
& genes*

~100M
chemical
molecules*

*For which ag 'big data' is available




From ag 'big data' to ag-innovation - the challenge




Evogene's proprietary approach

Harnessing ag 'big data' to achieve breakthrough ag-products




*For which ag 'big data' is available

Harnessing ag 'big data' through scientific understanding & computational technologies



Engine driving our innovation:
utilizing scientific understanding & computational technologies
to harness the potential of the Ag 'Big Data' revolution

Evogene's pathways for Ag-innovation




Core revenue model and partnerships

► Business model & partners

- **Initial revenues:** R&D and milestone payments from partners
- **Primary long-term revenues:** royalties from seed traits, ag-chemicals and ag-biologicals
- **Collaborations** with world leading seed and ag-chemical companies



Evogene's pathways for Ag-innovation



Improved seed traits

Market overview & potential




Rapidly growing market*



* Source: Phillips McDougall


Trait potential - per crop*



* Source: Team Analysis

Improved seed traits - Crop Enhancement













Current product program pipeline



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results, estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Improved seed traits - Crop Protection

Current product program pipeline

Crop	Trait	Partner	Discovery	Phase I POC	Phase II Early Dev.	Phase III Advanced Dev. & Regulation	Phase IV Pre Launch
Corn	1. Fusarium	MONSANTO					
	2. Lepidoptera						
	3. Coleoptera (Rootworm)						
	4. Beet Armyworm						
Soybean	5. Asian Rust	syngenta					
	6. Nematode						
	7. Lepidoptera						
	8. Hemiptera						
Banana	9. Black Sigatoka						
Cotton	10. Lygus Hesperus						

Evogene to Establish Research and Development Facility in the United States

February 9th, 2015

The establishment of the facility, which will be head by Dr. James Presnail, is a key component of the Company's previously disclosed entry into the field of insect control

REHOVOT, Israel – February 9, 2015 – Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, today announced it has signed a Letter of Intent with plans to establish a research and development facility in the Bio-Research and Development Growth (BRDG) Park, developed by Wexford Science & Technology, a BioMed Realty Company, on the campus of the Donald Danforth Plant Science Center in St. Louis, Missouri. The establishment of the facility is a



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the traits and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Improved seed traits

Collaboration with Monsanto - example

■ Collaboration period - 8 years

■ Traits

- **Crop Enhancement traits** - yield, drought tolerance, fertilizer utilization
- **Crop Protection traits** - Fusarium resistance in corn

■ Crops

- Corn, soybean, cotton, canola

■ Collaboration terms

- R&D and up-front payments - c.\$68m over collaboration period
- Milestone payments + royalties based on sales

■ Equity investment

- \$30m (including \$12m in recent IPO)

Evogene New Gene Optimization Program Being Incorporated into Yield & Environmental Stress Collaboration with Monsanto

February 4th, 2015



Addition of new capabilities follows entry of more than 1,000 Evogene identified and validated candidate genes to Monsanto's product development pipeline

REHOVOT, ISRAEL – February 4, 2015 – Evogene Ltd. (NYSE, TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today that its recently developed comprehensive gene optimization program is being incorporated into its multi-year collaboration with Monsanto Company. The addition of these new capabilities, which have been designed to optimize desired trait efficacy and potentially accelerate product development, follows the successful identification and validation by Evogene of more than one thousand genes that have entered Monsanto's product development pipeline. The collaboration, which was initiated in 2008 and extended in 2013, is focused on transgenic approaches for improved yield and enhanced stress tolerance in corn, soybean, cotton and canola. Genes that have been identified under the collaboration represent an important component of Monsanto's yield and environmental stress research and development program.

Gene discovery and trait optimization by Evogene

Yield

Drought

Fertilizer utilization



ATHLETE™



Gene2Product™



Model plant validation

Development and commercialization by Monsanto



Target plant validation and development



Regulatory




Improved seed traits - Crop Protection

Insect control - Our motivation and activity to date



Existing insect resistance seed traits - ~4.5B*



* Source: Context Network and Team Analysis, 2014

Dire need for innovation

Rising resistance to existing solutions



One solution (Bt toxins) does not fit all



* Context Network and Team Analysis

■ Market -

- Large potential
- Significant need due to increasing resistance

■ Evogene's offering -

- An innovative computational approach to delivering new MOA
- Several milestones successfully achieved to date


Evogene Announces Computational Discovery of Novel Microbial-Based Genes for Insect Control

August 3rd, 2015

Candidate genes, identified for their insecticidal properties, were discovered utilizing newly developed microbial database and dedicated computational platform

Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food, feed and biofuel industries, announced today a key milestone in its insect control program with the successful completion of the first computational discovery round for microbial-based genes with insecticidal properties. The discovery round utilized a unique computational technology infrastructure consisting of a proprietary microbial-based database and a dedicated analysis platform, BiomeMiner™.

Evogene's pathways for Ag-innovation




Innovative Ag-Chemicals

Market highlight



Huge market - ~\$55B* in 2014



* Source: Phillips McDougall, 2014

Need for innovation - herbicide sector

- Rising weed resistance



- Growing need for innovation




- Rising regulation pressure

Rising Glyphosate resistance



Less innovative ag-chemicals under development



Regulatory requirements becoming stricter




Innovative Ag-Chemicals - Crop Protection (Herbicides)

How does a herbicide work?



Herbicide: a chemical that inhibits a process in the weed that is essential to its life



Substantial growth in herbicide resistance → critical need for novel solutions

Innovative Ag-Chemicals - Crop Protection (Herbicides)

Current product program status




Crop	Application	Partner	Discovery (Protein & chemistry)	Development	Regulation & Registration
Row crops	1. <u>Non-selective</u> herbicide				
Broad leaves	2. Grasses <u>selective</u> herbicide				
Grasses	3. Broad leaves <u>selective</u> herbicide				

Evogene Announces Discovery and Validation of Novel Plant Targets for Herbicides

July 29th, 2015

- Newly discovered targets predicted to represent new modes of action

Rehovot, Israel – July 29, 2015 – Evogene Ltd. (NYSE: TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today the discovery and successful validation in plants of the first set of novel plant targets, representing a key milestone in its product program for new chemical herbicides. Targets for herbicides are vital plant macro-molecules taking part in essential biological processes in weeds ('modes of action'). The Evogene discovered targets will now be the subject of a unique methodology for the discovery of chemical molecules that can inhibit their functionality, resulting in weed death. These chemical molecules would then serve as the basis for the development of the active



Note: Any results, estimates, or calculations relating to probability of success at each phase of development may differ from company to company and across products. Furthermore, any such results estimates, calculations, or probabilities may differ depending on a range of varying factors, including, but not limited to, market conditions, changing regulations or longer than expected regulatory processes, the product type and the crops that are the target of research or collaboration and the amount of resources available, or devoted to, particular research or collaboration projects by us or our collaborators.

Innovative Ag-Chemicals - Crop Protection (Herbicides)

Collaboration with BASF - example



■ Collaboration period - ~3 years

■ **Objective** - Discovery & development of herbicidal hits with a new MOA that inhibit novel targets discovered by Evogene


■ **Activities** -

- Evogene to identify candidate chemicals for novel herbicides
- BASF to screen & validate the candidate chemicals and further develop successful candidates towards commercial products


BASF and Evogene Sign Collaboration Agreement for Novel Herbicide Discovery and Development

December 8th, 2015

Ludwigshafen, GERMANY and Rehovot, ISRAEL – Dec 8th, 2015 – BASF, the world's leading chemical company, and Evogene Ltd. (NYSE: TASE: EVGN), a leading company for the improvement of crop productivity, announced today the signing of a three-year collaboration for the discovery and development of novel herbicides.



Evogene's pathways for Ag-innovation




Ag-Biologicals

Market highlight and activity to date



An emerging market

Sources: Piper Jeffries 2013,
Agrow 2014



→ **Biostimulants** -
biological products for
crop enhancement

→ **Biopesticides** -
biological products for
crop protection

Why AgBiologicals?

- ✓ Relatively short time & low cost to product
- ✓ "Greener" and safer alternative to chemicals
- ✓ Mitigate emerging chemical resistance

Evogene's current activities - highlights



Proprietary seeds - Evofuel Ltd

A wholly owned development stage company



Castor today

- Traditional / family farming
 - Handpicked
 - Lack equipment
 - Poor seed quality
- Low productivity
 - World average - ~1ton/ha
- Limited supply
 - c.1.5m ha worldwide
 - c.\$1,500 per ton oil

Our castor

- Modern farming
 - Large scale
 - Fully automated
 - Significantly improved yields (100's %), rain fed
- Huge market potential
 - Short term - industrial uses
 - Longer term - biodiesel feedstock
- Attractive business model
 - Brazil and Argentina key markets
 - >5m ha potential in Brazil



Evofuel castor field, Brazil, 2014

Corporate ID

- Based in Rehovot, Israel; US R&D Center in St. Louis, MO
- ~200 FTEs, 80% R&D positions
- Key milestones:
 - 2002 - spin off from Compugen (NASDAQ:CGEN)
 - 2007 - lists on TASE (EVGN) ~\$34m (gross proceeds)
 - 2013 - lists on NYSE (EVGN) ~\$85m (gross proceeds)

Stock data

- Shares outstanding **~25.4M**
- Trading on **TASE** and **NYSE**

Cash position

(September 30, 2015)

- **~\$106.4M** in cash, short term bank deposits and marketable securities
- Operating cash burn for 9 month period **\$10.6M**



Thank you.

